Date:2/24/2010

xternalLink');" target='_blank' href="http://www.isilon.com/products/SyncIQ.php">SyncIQ® replicating data between the two clusters. Additionally, SeqWright is using Isilon's Backup Accelerator integrated with CommVault Simpana software to seamlessly backup mission-critical data from the 36NL cluster to tape for disaster recovery purposes. By using Isilon as an end-to-end storage solution for every stage in its genomic sequencing workflow, Unique Digital and SeqWright have created a highly reliable, easy to manage data management system that reduces costs, eliminates risk and improves productivity.

"At Unique Digital we look to address the entire storage infrastructure lifecycle, providing our customers with end-to-end solutions that increase productivity and eliminate risk," said Andy Pratt, president, Unique Digital. "Isilon is the perfect fit for SeqWright, as its tiered product lines and seamless integration with CommVault software enables us to deploy a complete solution from initial sequence to final backup, ensuring SeqWright can focus on delivering groundbreaking research and not on managing storage."

About Isilon Systems  

'/>"/>

SOURCE Isilon Systems Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related medicine news :

1. SeqWrights Partnership With Third Wave Contributes to FDA Success
2. Neutrons poised to play big role in future scientific advances
3. Senate Committee Advances Disastrous Idaho Health Freedom Act
4. Sunquest Advances Investment in Innovations Team
5. Large donation advances cancer research
6. Medical Advances Revolutionize Hip Replacement and Knee Replacement
7. Gene Findings in Autism, Blindness at Childrens Hospital Top National Lists of Medical Advances in 2009
8. Clinical trial advances new approach to re-sensitizing breast cancer
9. Reportlinker Adds Mesenchymal Stem Cells, Advances & Applications
10. New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer
11. Advances in Genetic Understanding and Treatment Protocols Lead to Significant Progress in Leukemia and Myeloproliferative Disorders